Why Allarity Therapeutics Stock Is Ripping Higher Wednesday
Portfolio Pulse from Erica Kollmann
Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares surged after the company reported promising initial data from Phase 2 trial of Ixempra for metastatic breast cancer patients. The company saw clinical benefits in all four evaluable cases. The stock is receiving attention from retail investors and is trending on social media. Shares of Allarity are currently trading 58% higher at $9.95.
July 05, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allarity Therapeutics' stock price surged after the company reported promising initial data from Phase 2 trial of Ixempra. The stock is also trending among retail investors.
The promising initial data from the Phase 2 trial of Ixempra has led to a surge in Allarity Therapeutics' stock price. The stock is also receiving attention from retail investors and is trending on social media, which could further drive the price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100